Bio-Rad Laboratories, Inc.Class A vs. Cytek Biosciences, Inc. Common Stock
BIO
Bio-Rad Laboratories, Inc.Class A
$381.76 +0.46%
VS CTKBCytek Biosciences, Inc. Common Stock
$4.44 -7.69%
Bio-Rad Laboratories, Inc.Class A (BIO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| BIO | CTKB | |
|---|---|---|
| Market Cap | $10.21 billion | $625.22 million |
| Revenue (TTM) | $2.59 billion | $206.71 million |
| Net Income (TTM) | $222.40 million | $-80,578,000 |
BIO leads on 3 of 3 size & scale factors.
Valuation
| BIO | CTKB | |
|---|---|---|
| P/E Ratio | 46.50 | — |
| Price / Book | 1.42 | 1.94 |
| Price / Sales | 3.94 | 3.02 |
BIO and CTKB split the valuation factors evenly.
Profitability
| BIO | CTKB | |
|---|---|---|
| Net Margin | 8.59% | -38.98% |
| Return on Equity | 3.10% | -25.03% |
BIO leads on 2 of 2 profitability factors.
Risk & Sentiment
| BIO | CTKB | |
|---|---|---|
| Short Interest | 2.44% | 0.01% |
CTKB leads on 1 of 1 risk & sentiment factors.
Dig deeper: BIO overview, BIO financials, CTKB overview, CTKB financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.